Adverse effects of corticosteroids and immunosuppressants
Adverse effects of corticosteroids and immunosuppressants ( 5 Questions)
A nurse is evaluating a client who has ulcerative colitis and is receiving infliximab (Remicade), a monoclonal antibody. What are some of the nursing considerations for this drug?
It should be given intravenously slowly over 2 hours to prevent infusion reactions such as fever, chills, rash, pruritus, and dyspnea . Infliximab is a monoclonal antibody that works by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can cause infusion reactions such as fever, chills, rash, pruritus, and dyspnea during or shortly after the infusion. These reactions are usually mild to moderate and can be prevented or managed by slowing down the infusion rate, premedicating with antihistamines, acetaminophen, or corticosteroids, and monitoring the vital signs and symptoms of the client. The nurse should instruct the client to report any signs of infusion reaction to the health care provider immediately.
It should be given with concomitant immunosuppressive agents such as azathioprine or methotrexate to enhance its efficacy and reduce antibody formation . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can lose its efficacy over time due to the formation of antibodies against it. These antibodies can also increase the risk of adverse effects such as infusion reactions, infection, or malignancy. To prevent or reduce antibody formation, infliximab should be given with concomitant immunosuppressive agents such as azathioprine or methotrexate. These agents can also enhance the efficacy of infliximab by suppressing the immune system and reducing inflammation. The nurse should instruct the client to take these agents as prescribed by their doctor and to monitor their blood counts and liver function tests regularly.
It should be given with prophylactic antibiotics or antifungals to prevent infection due to suppression of the immune system . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can suppress the immune system and increase the risk of serious or fatal infections such as tuberculosis, fungal infections, bacterial infections, viral infections, or parasitic infections. To prevent or treat these infections, infliximab should be given with prophylactic antibiotics or antifungals as prescribed by their doctor. The nurse should instruct the client to undergo screening tests for latent tuberculosis and hepatitis B before starting infliximab therapy and to report any signs of infection (such as fever, chills, sore throat, cough, or wound drainage) to their doctor. The nurse should also advise the client to avoid contact with people who have infections and to receive inactivated vaccines as recommended by their doctor.
It should be monitored for signs of hypersensitivity, infection, malignancy, and hepatotoxicity during and after the infusion . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can cause serious adverse effects such as hypersensitivity reactions (such as anaphylaxis or serum sickness), infection (such as tuberculosis or fungal infections), malignancy (such as lymphoma or skin cancer), and hepatotoxicity (such as elevated liver enzymes or liver failure). The nurse should monitor the client for signs and symptoms of these adverse effects during and after the infusion and intervene as appropriate. The nurse should also educate the client about the potential adverse effects of infliximab and how to prevent or manage them.
No explanation
A. It should be given intravenously slowly over 2 hours to prevent infusion reactions such as fever, chills, rash, pruritus, and dyspnea . Infliximab is a monoclonal antibody that works by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can cause infusion reactions such as fever, chills, rash, pruritus, and dyspnea during or shortly after the infusion. These reactions are usually mild to moderate and can be prevented or managed by slowing down the infusion rate, premedicating with antihistamines, acetaminophen, or corticosteroids, and monitoring the vital signs and symptoms of the client. The nurse should instruct the client to report any signs of infusion reaction to the health care provider immediately.
B. It should be given with concomitant immunosuppressive agents such as azathioprine or methotrexate to enhance its efficacy and reduce antibody formation . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can lose its efficacy over time due to the formation of antibodies against it. These antibodies can also increase the risk of adverse effects such as infusion reactions, infection, or malignancy. To prevent or reduce antibody formation, infliximab should be given with concomitant immunosuppressive agents such as azathioprine or methotrexate. These agents can also enhance the efficacy of infliximab by suppressing the immune system and reducing inflammation. The nurse should instruct the client to take these agents as prescribed by their doctor and to monitor their blood counts and liver function tests regularly.
C. It should be given with prophylactic antibiotics or antifungals to prevent infection due to suppression of the immune system . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can suppress the immune system and increase the risk of serious or fatal infections such as tuberculosis, fungal infections, bacterial infections, viral infections, or parasitic infections. To prevent or treat these infections, infliximab should be given with prophylactic antibiotics or antifungals as prescribed by their doctor. The nurse should instruct the client to undergo screening tests for latent tuberculosis and hepatitis B before starting infliximab therapy and to report any signs of infection (such as fever, chills, sore throat, cough, or wound drainage) to their doctor. The nurse should also advise the client to avoid contact with people who have infections and to receive inactivated vaccines as recommended by their doctor.
D. It should be monitored for signs of hypersensitivity, infection, malignancy, and hepatotoxicity during and after the infusion . Infliximab is a monoclonal antibody that works by blocking the action of TNF-alpha, a cytokine that mediates inflammation and tissue damage in ulcerative colitis. Infliximab can cause serious adverse effects such as hypersensitivity reactions (such as anaphylaxis or serum sickness), infection (such as tuberculosis or fungal infections), malignancy (such as lymphoma or skin cancer), and hepatotoxicity (such as elevated liver enzymes or liver failure). The nurse should monitor the client for signs and symptoms of these adverse effects during and after the infusion and intervene as appropriate. The nurse should also educate the client about the potential adverse effects of infliximab and how to prevent or manage them.